Rxivist logo

Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres. ### Competing Interest Statement Sarah Gilbert and Teresa Lambe are named on a patent application covering ChAdOx1 nCoV-19. The remaining authors declare no competing interests. The funders played no role in the conceptualisation, design, data collection, analysis, the decision to publish, or preparation of the manuscript.

Download data

  • Downloaded 5,031 times
  • Download rankings, all-time:
    • Site-wide: 895 out of 103,749
    • In immunology: 35 out of 3,257
  • Year to date:
    • Site-wide: 300 out of 103,749
  • Since beginning of last month:
    • Site-wide: 2,895 out of 103,749

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)